D
Akebia Therapeutics, Inc.
AKBA
$1.73
-$0.15-7.98%
D
Sell
5/15/2023Upgraded
Akebia Therapeutics, Inc. (AKBA) was upgraded to D- from E+ on 5/15/2023 due to an increase in the valuation index and total return index.
Akebia Therapeutics, Inc. (AKBA) was upgraded to D- from E+ on 5/15/2023 due to an increase in the valuation index and total return index.
E
Sell
3/14/2023Downgrade
Akebia Therapeutics, Inc. (AKBA) was downgraded to E+ from D on 3/14/2023 due to a decline in the valuation index.
Akebia Therapeutics, Inc. (AKBA) was downgraded to E+ from D on 3/14/2023 due to a decline in the valuation index.
D
Sell
3/6/2023Upgraded
Akebia Therapeutics, Inc. (AKBA) was upgraded to D from D- on 3/6/2023 due to an increase in the volatility index and total return index.
Akebia Therapeutics, Inc. (AKBA) was upgraded to D from D- on 3/6/2023 due to an increase in the volatility index and total return index.
D
Sell
2/23/2023Upgraded
Akebia Therapeutics, Inc. (AKBA) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
Akebia Therapeutics, Inc. (AKBA) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
Akebia Therapeutics, Inc. (AKBA) was downgraded to E+ from D- on 2/8/2023 due to a decline in the valuation index.
Akebia Therapeutics, Inc. (AKBA) was downgraded to E+ from D- on 2/8/2023 due to a decline in the valuation index.
D
Sell
11/7/2022Downgrade
Akebia Therapeutics, Inc. (AKBA) was downgraded to D- from D on 11/7/2022 due to a noticeable decline in the growth index, solvency index and valuation index. Earnings per share declined from $0.15 to -$0.2821, debt to equity increased from 1.65 to 5.07, and EBIT declined 199.09% from $48.43M to -$47.99M.
Akebia Therapeutics, Inc. (AKBA) was downgraded to D- from D on 11/7/2022 due to a noticeable decline in the growth index, solvency index and valuation index. Earnings per share declined from $0.15 to -$0.2821, debt to equity increased from 1.65 to 5.07, and EBIT declined 199.09% from $48.43M to -$47.99M.
D
Sell
5/16/2022Upgraded
Akebia Therapeutics, Inc. (AKBA) was upgraded to D from E+ on 05/16/2022.
Akebia Therapeutics, Inc. (AKBA) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Akebia Therapeutics, Inc. (AKBA) was downgraded to E+ from D on 5/13/2022 due to a decline in the solvency index and total return index. Debt to equity increased from 1.34 to 3.93.
Akebia Therapeutics, Inc. (AKBA) was downgraded to E+ from D on 5/13/2022 due to a decline in the solvency index and total return index. Debt to equity increased from 1.34 to 3.93.
D
Sell
5/4/2022Upgraded
Akebia Therapeutics, Inc. (AKBA) was upgraded to D from E+ on 05/04/2022.
Akebia Therapeutics, Inc. (AKBA) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
Akebia Therapeutics, Inc. (AKBA) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
Akebia Therapeutics, Inc. (AKBA) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/21/2022Upgraded
Akebia Therapeutics, Inc. (AKBA) was upgraded to D from E+ on 04/21/2022.
Akebia Therapeutics, Inc. (AKBA) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Akebia Therapeutics, Inc. (AKBA) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index, solvency index and total return index. Debt to equity increased from 0.75 to 1.34, and the quick ratio declined from 1.38 to 0.8.
Akebia Therapeutics, Inc. (AKBA) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index, solvency index and total return index. Debt to equity increased from 0.75 to 1.34, and the quick ratio declined from 1.38 to 0.8.
D
Sell
11/9/2021Upgraded
Akebia Therapeutics, Inc. (AKBA) was upgraded to D from E+ on 11/09/2021.
Akebia Therapeutics, Inc. (AKBA) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Akebia Therapeutics, Inc. (AKBA) was downgraded to E+ from D- on 11/8/2021 due to a decline in the valuation index, total return index and volatility index.
Akebia Therapeutics, Inc. (AKBA) was downgraded to E+ from D- on 11/8/2021 due to a decline in the valuation index, total return index and volatility index.
D
Sell
10/21/2021Downgrade
Akebia Therapeutics, Inc. (AKBA) was downgraded to D- from D on 10/21/2021 due to a significant decline in the growth index, total return index and volatility index. EBIT declined 82.98% from -$43.36M to -$79.34M, and earnings per share declined from -$0.4523 to -$0.5147.
Akebia Therapeutics, Inc. (AKBA) was downgraded to D- from D on 10/21/2021 due to a significant decline in the growth index, total return index and volatility index. EBIT declined 82.98% from -$43.36M to -$79.34M, and earnings per share declined from -$0.4523 to -$0.5147.
D
Sell
5/26/2020Downgrade
Akebia Therapeutics, Inc. (AKBA) was downgraded to D from D+ on 5/26/2020 due to a decline in the valuation index.
Akebia Therapeutics, Inc. (AKBA) was downgraded to D from D+ on 5/26/2020 due to a decline in the valuation index.
D
Sell
5/8/2020Upgraded
Akebia Therapeutics, Inc. (AKBA) was upgraded to D+ from D on 5/8/2020 due to a large increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.7916 to -$0.4731, EBIT increased 35.99% from -$74.91M to -$47.95M, and total revenue increased 27.21% from $69.56M to $88.48M.
Akebia Therapeutics, Inc. (AKBA) was upgraded to D+ from D on 5/8/2020 due to a large increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.7916 to -$0.4731, EBIT increased 35.99% from -$74.91M to -$47.95M, and total revenue increased 27.21% from $69.56M to $88.48M.
D
Sell
3/16/2020Upgraded
Akebia Therapeutics, Inc. (AKBA) was upgraded to D from D- on 3/16/2020 due to a large increase in the total return index, volatility index and growth index.
Akebia Therapeutics, Inc. (AKBA) was upgraded to D from D- on 3/16/2020 due to a large increase in the total return index, volatility index and growth index.
D
Sell
5/15/2019Downgrade
Akebia Therapeutics, Inc. (AKBA) was downgraded to D- from D on 5/15/2019 due to a decline in the solvency index and efficiency index. Debt to equity increased from 0.02 to 0.06, net income declined 20.59% from -$60.05M to -$72.42M, and the quick ratio declined from 1.27 to 1.07.
Akebia Therapeutics, Inc. (AKBA) was downgraded to D- from D on 5/15/2019 due to a decline in the solvency index and efficiency index. Debt to equity increased from 0.02 to 0.06, net income declined 20.59% from -$60.05M to -$72.42M, and the quick ratio declined from 1.27 to 1.07.
D
Sell
3/29/2019Upgraded
Akebia Therapeutics, Inc. (AKBA) was upgraded to D from D- on 3/29/2019 due to an increase in the solvency index, valuation index and efficiency index. Total capital increased 356.66% from $142.54M to $650.93M.
Akebia Therapeutics, Inc. (AKBA) was upgraded to D from D- on 3/29/2019 due to an increase in the solvency index, valuation index and efficiency index. Total capital increased 356.66% from $142.54M to $650.93M.
D
Sell
10/16/2017Downgrade
Akebia Therapeutics, Inc. (AKBA) was downgraded to D- from D on 10/16/2017 due to a decline in the efficiency index and valuation index.
Akebia Therapeutics, Inc. (AKBA) was downgraded to D- from D on 10/16/2017 due to a decline in the efficiency index and valuation index.
D
Sell
8/12/2016Upgraded
Amber Road, Inc. (AKBA) was upgraded to D from D- on 8/12/2016 due to an increase in the growth index and efficiency index. Earnings per share increased from -$0.2151 to -$0.1784, net income increased 16.63% from -$5.69M to -$4.74M, and EBIT increased 14.8% from -$5.17M to -$4.41M.
Amber Road, Inc. (AKBA) was upgraded to D from D- on 8/12/2016 due to an increase in the growth index and efficiency index. Earnings per share increased from -$0.2151 to -$0.1784, net income increased 16.63% from -$5.69M to -$4.74M, and EBIT increased 14.8% from -$5.17M to -$4.41M.
D
Sell
7/18/2016Downgrade
Amber Road, Inc. (AKBA) was downgraded to D- from D on 7/18/2016 due to a decline in the total return index, volatility index and valuation index.
Amber Road, Inc. (AKBA) was downgraded to D- from D on 7/18/2016 due to a decline in the total return index, volatility index and valuation index.
D
Sell
6/27/2016Upgraded
Amber Road, Inc. (AKBA) was upgraded to D from D- on 6/27/2016 due to a noticeable increase in the total return index and efficiency index. Net income increased 14.46% from -$6.65M to -$5.69M.
Amber Road, Inc. (AKBA) was upgraded to D from D- on 6/27/2016 due to a noticeable increase in the total return index and efficiency index. Net income increased 14.46% from -$6.65M to -$5.69M.
D
Sell
3/15/2016Downgrade
Amber Road, Inc. (AKBA) was downgraded to D- from D on 3/15/2016 due to a large decline in the solvency index, volatility index and total return index. Debt to equity increased from 0.39 to 0.42, and the quick ratio declined from 1.07 to 0.99.
Amber Road, Inc. (AKBA) was downgraded to D- from D on 3/15/2016 due to a large decline in the solvency index, volatility index and total return index. Debt to equity increased from 0.39 to 0.42, and the quick ratio declined from 1.07 to 0.99.
D
Sell
4/1/2015Upgraded
Amber Road, Inc. (AKBA) was upgraded to D from D- on 4/1/2015 due to an increase in the growth index, valuation index and efficiency index. EBIT increased 41.18% from -$919.2 to -$1.3M, total revenue increased 7.25% from $16.42M to $17.61M, and total capital increased 1.06% from $67.7M to $68.42M.
Amber Road, Inc. (AKBA) was upgraded to D from D- on 4/1/2015 due to an increase in the growth index, valuation index and efficiency index. EBIT increased 41.18% from -$919.2 to -$1.3M, total revenue increased 7.25% from $16.42M to $17.61M, and total capital increased 1.06% from $67.7M to $68.42M.
D
Sell
12/1/2014Upgraded
Amber Road, Inc. (AKBA) was upgraded to D- from E on 12/1/2014 due to an increase in the solvency index.
Amber Road, Inc. (AKBA) was upgraded to D- from E on 12/1/2014 due to an increase in the solvency index.
E
Sell
11/20/2014Downgrade
Amber Road, Inc. (AKBA) was downgraded to E from E+ on 11/20/2014 due to a decline in the growth index, valuation index and efficiency index. Operating cash flow declined 97.97% from -$8.75M to -$177.2, EBIT declined 53.17% from -$1.96M to -$919.2, and total capital declined 1.15% from $68.49M to $67.7M.
Amber Road, Inc. (AKBA) was downgraded to E from E+ on 11/20/2014 due to a decline in the growth index, valuation index and efficiency index. Operating cash flow declined 97.97% from -$8.75M to -$177.2, EBIT declined 53.17% from -$1.96M to -$919.2, and total capital declined 1.15% from $68.49M to $67.7M.
E
Sell
11/7/2014Upgraded
Amber Road, Inc. (AKBA) was upgraded to E+ from E on 11/7/2014 due to an increase in the valuation index.
Amber Road, Inc. (AKBA) was upgraded to E+ from E on 11/7/2014 due to an increase in the valuation index.
E
Sell
9/22/2014Downgrade
Amber Road, Inc. (AKBA) was downgraded to E from E+ on 9/22/2014 due to a decline in the volatility index and total return index.
Amber Road, Inc. (AKBA) was downgraded to E from E+ on 9/22/2014 due to a decline in the volatility index and total return index.
E
Sell
9/2/2014Upgraded
Amber Road, Inc. (AKBA) was upgraded to E+ from E on 9/2/2014 due to a large increase in the solvency index, growth index and total return index. Operating cash flow increased 4,882.35% from -$175.6 to -$8.75M, and total revenue increased 5.47% from $14.99M to $15.81M.
Amber Road, Inc. (AKBA) was upgraded to E+ from E on 9/2/2014 due to a large increase in the solvency index, growth index and total return index. Operating cash flow increased 4,882.35% from -$175.6 to -$8.75M, and total revenue increased 5.47% from $14.99M to $15.81M.
E
Sell
6/13/2014None
Akebia Therapeutics, Inc. (AKBA) was downgraded to E from U on 06/13/2014.
Akebia Therapeutics, Inc. (AKBA) was downgraded to E from U on 06/13/2014.
NASDAQ
04/04/2025 12:55PM Eastern
Quotes delayed
